|
**Overview**: **Biofire GI Stool Profile****Introduction**: The Biofire GI Stool Profile is a diagnostic tool designed to detect gastrointestinal pathogens using stool samples. Associated with conditions like bacterial gastroenteritis and parasitic infections, these disorders present with diarrhea, abdominal pain, and severe complications if untreated, particularly in individuals with gastrointestinal symptoms. Per the 2023 Bacteriology, Virology, and Parasitology guidelines, the test employs PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for GI infection screening in clinical settings. This diagnostic falls under GI infection screening and targets individuals with suspected gastrointestinal infections, addressing the challenge of accurate pathogen assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its stool-based approach ensures reliable detection.**Other Names**: Biofire GI Pfl.**FDA Status**: FDA approved, CLIA certified for bacteriology, virology, and parasitology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by microbiology labs, this test advanced GI pathogen detection.**Purpose**: The test screens for 22 parameters including Campylobacter to guide GI infection assessment, assess pathogen presence, and inform treatment and prevention strategies.**Test Parameters**: 1. Campylobacter, 2. Clostridium difficile, 3. Plesiomonas shigelloides, 4. Salmonella, 5. Yersinia enterocolitica, 6. Vibrio, 7. Escherichia coli (EHEC), 8. Escherichia coli (ETEC), 9. Escherichia coli (EPEC), 10. Shigella, 11. Cryptosporidium, 12. Cyclospora cayetanensis, 13. Entamoeba histolytica, 14. Giardia lamblia, 15. Adenovirus F 40/41, 16. Astrovirus, 17. Norovirus GI/GII, 18. Rotavirus A, 19. Sapovirus, 20. Aeromonas, 21. Helicobacter pylori, 22. Enteroaggregative E. coli (EAEC).**Pretest Condition**: No fasting required; patients should report diarrhea, abdominal pain, or recent GI symptoms.**Specimen**: 5 g stool in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 1 month at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on diarrhea, abdominal pain, prior GI infections, or family history of infectious diseases, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated GI infections including dehydration, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antibiotic use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible GI infections, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early infection stages.**Specialist Consultation**: General practitioners or specialists in gastroenterology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Stool culture or endoscopy for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Bacteriology, Virology, and Parasitology Guidelines 2023, Journal of Infectious Diseases 2024, Microbiology 2025. |
